Gabrielle Couchy Selected Research

Liver Cell Adenoma (Hepatocellular Adenoma)

1/2020	Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas.
1/2018	Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas.
12/2017	Focal β-catenin mutation identified on formalin-fixed and paraffin-embedded inflammatory hepatocellular adenomas.
4/2017	Malignant transformation of a β-catenin inflammatory adenoma due to an S45 β-catenin-activating mutation present 12 years before.
1/2017	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.
1/2016	Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis.
9/2014	Characterization of a novel PXR isoform with potential dominant-negative properties.
4/2014	Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.
1/2009	Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours.
9/2007	Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gabrielle Couchy Research Topics

Disease

37	Neoplasms (Cancer) 12/2021 - 06/2008
16	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 09/2007
16	Renal Cell Carcinoma (Grawitz Tumor) 12/2021 - 01/2014
10	Liver Cell Adenoma (Hepatocellular Adenoma) 01/2020 - 09/2007
7	Carcinogenesis 01/2022 - 06/2008
5	Adenoma (Adenomas) 04/2017 - 06/2008
4	Liver Neoplasms (Liver Cancer) 01/2019 - 11/2016
3	Hypoxia (Hypoxemia) 06/2021 - 03/2015
3	Hemorrhage 01/2018 - 08/2009
2	Neoplasm Metastasis (Metastasis) 11/2021 - 03/2021
2	Focal Nodular Hyperplasia 07/2008 - 06/2008
1	Polyploidy 01/2020
1	Hypersensitivity (Allergy) 01/2019
1	Kidney Neoplasms (Kidney Cancer) 10/2018
1	Cholestasis 12/2017
1	Liver Diseases (Liver Disease) 01/2016
1	Carcinoma (Carcinomatosis) 04/2014
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2014
1	Primary Myelofibrosis (Myelosclerosis) 12/2013
1	Genomic Instability 01/2012

Drug/Important Bio-Agent (IBA)

10	CateninsIBA 01/2022 - 05/2012
8	Proteins (Proteins, Gene)FDA Link 06/2021 - 01/2009
7	beta CateninIBA 01/2020 - 09/2007
7	Sunitinib (Sutent)FDA Link 10/2019 - 01/2014
6	MicroRNAs (MicroRNA)IBA 06/2021 - 06/2008
6	Interleukin-6 (Interleukin 6)IBA 01/2020 - 01/2009
5	Tyrosine Kinase InhibitorsIBA 12/2021 - 12/2013
5	Biomarkers (Surrogate Marker)IBA 06/2021 - 12/2016
4	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 12/2021 - 04/2018
4	Messenger RNA (mRNA)IBA 01/2020 - 01/2012
3	ParaffinIBA 12/2021 - 04/2017
3	RNA (Ribonucleic Acid)IBA 12/2021 - 01/2019
3	Glutamate-Ammonia Ligase (Glutamine Synthetase)IBA 04/2017 - 11/2016
2	Formaldehyde (Formol)FDA Link 12/2021 - 12/2017
2	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2020 - 10/2015
2	TOR Serine-Threonine KinasesIBA 01/2020 - 11/2016
2	NivolumabIBA 10/2019 - 10/2019
2	Bevacizumab (Avastin)FDA Link 10/2019 - 01/2014
2	pazopanib FDA Link 01/2019 - 01/2018
2	Cyclin A2IBA 12/2018 - 10/2015
2	CyclinsIBA 12/2018 - 10/2015
2	Aflatoxin B1 (Aflatoxin B)IBA 11/2017 - 05/2015
2	Hepatocyte Nuclear FactorsIBA 05/2017 - 01/2017
2	C-Reactive ProteinIBA 04/2017 - 01/2016
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 12/2016 - 06/2008
2	Mitogen-Activated Protein KinasesIBA 11/2016 - 05/2012
2	LigandsIBA 03/2015 - 01/2009
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 06/2021
1	Small Untranslated RNAIBA 03/2021
1	MTOR InhibitorsIBA 01/2020
1	DNA (Deoxyribonucleic Acid)IBA 01/2020
1	Apolipoproteins B (ApoB)IBA 01/2020
1	ApolipoproteinsIBA 01/2020
1	AlbuminsIBA 01/2020
1	Immunologic Factors (Immunomodulators)IBA 01/2020
1	Janus KinasesIBA 01/2020
1	atezolizumabIBA 10/2019
1	IpilimumabIBA 10/2019
1	cabozantinibIBA 01/2019
1	Pharmaceutical PreparationsIBA 01/2019
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 01/2019
1	Phosphotransferases (Kinase)IBA 01/2019
1	Sorafenib (BAY 43-9006)FDA Link 01/2019
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2018
1	Argininosuccinate Synthase (Argininosuccinate Synthetase)IBA 01/2018
1	Reticulin (Reticular Fiber)IBA 12/2017
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 10/2017
1	ARQ 197IBA 08/2017
1	Paclitaxel (Taxol)FDA LinkGeneric 08/2017
1	5- ((2,6- dichlorobenzyl)sulfonyl)- 3- ((3,5- dimethyl- 4- ((2- (pyrrolidin- 1- ylmethyl)pyrrolidin- 1- yl)carbonyl)- 1H- pyrrol- 2- yl)methylene)- 1,3- dihydro- 2H- indol- 2- oneIBA 08/2017
1	Vinblastine (Vinblastine Sulfate)FDA Link 08/2017
1	JNJ38877605IBA 08/2017
1	Transcription Factors (Transcription Factor)IBA 05/2017
1	Metalloproteases (Metalloproteinases)IBA 01/2017
1	Tiopronin (Thiola)FDA Link 01/2017
1	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 12/2016
1	Glutamine (L-Glutamine)FDA Link 12/2016
1	Matrix Metalloproteinase 14 (MT1-MMP)IBA 11/2016
1	TransposasesIBA 11/2016
1	Cyclin D1IBA 11/2016
1	CollagenIBA 11/2016
1	Transcription Factor 7-Like 2 ProteinIBA 11/2016
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 11/2016
1	Serum Amyloid A Protein (Serum Amyloid A)IBA 01/2016
1	Keratins (Keratin)IBA 01/2016
1	MethyltransferasesIBA 10/2015
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2015
1	Lysine (L-Lysine)FDA Link 10/2015
1	LuciferasesIBA 09/2014
1	Oral ContraceptivesIBA 04/2014
1	Biological ProductsIBA 03/2014
1	thiamine triphosphorate (TTP)IBA 01/2014
1	ruxolitinibIBA 12/2013
1	ChromatinIBA 05/2012
1	InterferonsIBA 01/2012

Therapy/Procedure

5	Therapeutics 01/2020 - 03/2014
1	Metastasectomy 10/2018
1	Hepatectomy 04/2017
1	Precision Medicine 11/2016
1	Drug Tapering 10/2014